June 05, 2021
Article
Bemarituzumab is an investigational, potential first-in-class targeted antibody designed to block specific fibroblast growth factors from binding and activating FGFR2b.
May 20, 2021
Median disease-free survival was twice as long in patients who received nivolumab compared to patients who received a placebo.
April 16, 2021
Nivolumab is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival compared to chemotherapy alone in this patient population.
April 12, 2021
A presentation at the Community Oncology Alliance 2021 Virtual Conference focused on the latest developments in gastrointestinal oncology and how the field of gastroesophageal cancer is responding to 3 major, practice-changing trials.
The data were presented for the first time at the virtual 2021 American Association for Cancer Research (AACR) Annual Meeting, April 10-15, 2021.
February 16, 2021
Data from the FIGHT trial suggests that approximately 30% of patients with non-human epidermal growth factor 2-positive GEJ cancers overexpress fibroblast growth factor receptor 2.
February 11, 2021
The efficacy results demonstrated that there were 4 patients with confirmed partial response, and an additional 3 patients had stable disease lasting 16 weeks or longer.
January 18, 2021
The FDA approved Enhertu in January 2020 for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
October 29, 2020
The FDA granted priority review to a supplemental biologics license application for trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma.
October 01, 2020
Pharmacists can play an integral role in collaborating with physicians to manage patient therapy.
